Clinical trials: Esophagogastric Junction Disorder
Gastric Cancer
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.
- Trial name
- NCT05396326
- Testing
- Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE)
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastroesophageal Reflux Disease
Structure and Function of the Gastro-esophageal Junction
Aims of research project: To identify key features of the gastro-esophageal junction (structure and function) that protects the esophagus from gastro-esophageal reflux investigated by combined high resolution manometry and…
- Trial name
- NCT01053585
- Testing
- Baclofen
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Gastric Cancer
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00514020
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive…
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
- Trial name
- NCT04492488
- Testing
- MRG002
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- Shanghai Miracogen Inc.
Esophageal Cancer
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving cisplatin and irinotecan hydrochloride together with radiation therapy works in treating patients with esophageal cancer or gastroesophageal junction cancer that can be removed by…
- Trial name
- NCT00316862
- Testing
- cisplatin, irinotecan hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer, Gastroesophageal Cancer
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance
- Trial name
- NCT04555304
- Testing
- KH903 + Paclitaxel
- Volunteers
- 81 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Gastric Cancer
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
- Trial name
- NCT01956149
- Testing
- Cabazitaxel
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Gastric Cancer, Cancer of the Stomach
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
- Trial name
- NCT03662659
- Testing
- BMS-986213, Nivolumab, XELOX
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Gastric Adenocarcinoma, Pancreatic Cancer
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic…
- Conditions
- Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04581473
- Testing
- CT041 autologous CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- Where
- 24 sites in China
- Volunteers
- 192 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
In this trial, FLOT will be evaluated as therapy option for elderly patients (>65 years) with advanced gastric cancer in comparison to the well established FLO scheme.
- Trial name
- NCT00737373
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Krankenhaus Nordwest
Gastric Cancer, Esophagogastric Junction Adenocarcinoma
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a…
- Trial name
- NCT06461910
- Testing
- Serplulimab, thymalfasin, Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zekuan Xu
Stomach Neoplasms
Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer
Rationale: Adjuvant chemoradiation considered as standard of care after curative surgery for adenocarcinoma of stomach and gastroesophageal cancer.
- Trial name
- NCT00420394
- Testing
- Chemotherapy, surgery, radiotherapy
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Soroka University Medical Center
Esophageal Cancer, Adenocarcinoma, Esophageal
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when…
- Conditions
- Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
- Trial name
- POWERRANGER (NCT01404156)
- Testing
- (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Dr. Gordon Buduhan
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood.
- Conditions
- Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
- Trial name
- NCT06157892
- Testing
- disitamab vedotin, tucatinib
- Where
- 135 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophageal Cancer
A Study Involving Neoadjuvant Chemoradiotherapy With Hypofractionated Radiotherapy in Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma
An open-label, single-centre, non-randomized, Phase II trial in patients with esophageal adenocarcinoma. This study aims to show that delivering hypofractionated neoadjuvant concurrent chemoradiotherapy is is equally effective as…
- Trial name
- NCT05370144
- Testing
- Hypofractionated radiotherapy
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- AHS Cancer Control Alberta
Stomach Neoplasms, Esophageal Neoplasms
Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers
The incidence of cancer of the esophagogastric junction has rapidly risen in recent three decades, and surgery still remains the optimum therapy.
- Trial name
- NCT01911832
- Testing
- esophagojejunostomy after total gastrectomy, Roux-en-Y gastrojejunostomy after subtotal gastrectomy, wide tube reconstruction after subtotal gastrectomy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Gastric Carcinoma Stage IV, Esophagogastric Junction Adenocarcinoma Stage IV
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
Patients with metastatic adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations .
- Trial name
- IRIGA (NCT04442984)
- Testing
- Irinotecan, Oxaliplatin, 5-FU
- Where
- Russia
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center